Drug intelligence / Profile preview

IMT-104

Development stage: Preclinical
Lead developer: IMMUSE
Modality: Small Molecules
Administration: Oral, Intraperitoneal

Overview

IMT-104 is a **preclinical small-molecule immunotherapy** being developed by **IMMUSE** for **solid cancers**. Based on IMMUSE's disclosed pipeline framing, it belongs to the company's new chemical entity program focused on **modulating the tumor microenvironment** and **reversing exhausted or dysfunctional T-cell states** in solid tumors. The specific molecular target and detailed mechanism have not been publicly disclosed, so it is best described as an investigational small-molecule cancer immunotherapy candidate in early development.

Targets

MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)

Beyond the preview

Go deeper on IMT-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMT-104.

Explore the full profile